NEW HAVEN, Conn.--CuraGen announced the expansion of its proprietary database to include more than 70,000 novel human sequences, organized into large gene segments or assemblies, that are not publicly available. The database will serve as the basis for developing protein therapeutic drugs, human antibody drug targets, and for identifying small molecule drug targets. CuraGen researchers will also use the data to mine public databases for data useful in assembling full-length genes and discovering additional drug targets.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.